advertisement
Abstract #46683 Published in IGR 13-3
Diurnal intraocular pressure efficacy of the timolol-brimonidine fixed combination and the timolol-dorzolamide fixed combination as a first choice therapy in patients with pseudoexfoliation glaucoma
Yuksel N; Gok M; Altintas O; Caglar YCurrent Eye Research 2011; 36: 804-808
Purpose: To evaluate the 6- month daytime efficacy of a fixed combination of timolol and brimonidine (BTFC) versus a timolol and dorzolamide fixed combination (DTFC) as a first choice therapy in patients with pseudoexfoliation glaucoma (PXG). Methods: This study was a randomized, prospective, investigator-masked, 6-month comparison of twice-daily administration of BTFC versus DTFC in 60 newly diagnosed PXG patients. Results: Mean baseline untreated IOPs were 25.5(plus or minus)2.6 mmHg and 26.2(plus or minus)2.1 mmHg in the DTFC and BTFC groups, respectively. Mean intraocular pressure (IOP) reductions ranged from -7.3(plus or minus)1.9 to -8.1(plus or minus)2.0 mmHg for the DTFC group and from -7.5(plus or minus)2.0 to -8.6(plus or minus)2.6 mmHg for the BTFC group. No significant differences between the two treatment groups could be found. At month 6, the mean diurnal IOP was 17.5(plus or minus)2.5 mmHg (31.3%) for the DTFC group and 18.0(plus or minus)2.8mm Hg (31.7%) for BTFC. As compared with baseline, mean diurnal IOP decreased by 7.9(plus or minus)1.9 mmHg in the DTFC and 8.2(plus or minus)1.5mmHg in the BTFC, the difference between the groups was not statistically significant (p=0.6). No statistical difference in terms of adverse events was found either. Conclusion: Both fixed combinations were effective at lowering IOP in PXG. This study suggests that the daytime diurnal IOP is not statistically different when DTFC or BTFC is used as a first choice therapy in patients with PXG.
N. Yuksel. Kocaeli University, Ophthalmology Department, Umuttepe Izmit, Kocaeli, Turkey.
Classification:
9.4.4.1 Exfoliation syndrome (Part of: 9 Clinical forms of glaucomas > 9.4 Glaucomas associated with other ocular and systemic disorders > 9.4.4 Glaucomas associated with disorders of the lens)
11.13.3 Betablocker and brimonidine (Part of: 11 Medical treatment > 11.13 Combination therapy)
11.13.2 Betablocker and carbon anhydrase inhibitor (Part of: 11 Medical treatment > 11.13 Combination therapy)